Discover the complete record of transactions filed by Patrick LANGLOIS, Associé-Gérant de PJL CONSEILS. Director active across 1 companies, notably Innate Pharma. Aggregated, 1 disclosures have been recorded. Total volume traded: €21k. The latest transaction was disclosed on 24 November 2021 — Acquisition. Regulator: AMF. The full history is free.
1 of 1 declaration
Patrick Langlois is a seasoned governance and finance executive with a long-standing connection to listed life-sciences companies, especially Innate Pharma, where he serves on the Supervisory Board. His most notable current role is General Partner of PJL CONSEILS, a position he has held since 2005, alongside board mandates in several biopharmaceutical companies. At Innate Pharma, he was appointed on the proposal of the Fonds Stratégique d’Investissement, reflecting the strategic nature of his profile for supporting innovative growth companies. Langlois built the core of his career within Rhône-Poulenc, which he joined in 1975. Over time, he held senior financial and leadership responsibilities, becoming CFO of Rhône-Poulenc in 1997. He later moved to Aventis, where he served as Chief Financial Officer and Executive Vice President from 2002 to 2004. Innate Pharma’s corporate documents also note that he previously held executive committee and finance leadership roles at Rhône-Poulenc Rorer, and later managed high-level financial and corporate development responsibilities across the group’s international operations. His expertise lies in corporate finance, governance, strategic oversight, and the management of complex pharmaceutical organizations. Having spent decades in major international pharma groups, he brings deep experience in transformation, post-merger integration, capital allocation, and value creation. After leaving day-to-day executive roles, he has applied this background to biotech and healthcare companies, offering disciplined insight into financial, regulatory, and strategic issues that matter to innovative life-sciences businesses. At Innate Pharma, his contribution fits a broader governance framework aimed at supporting a publicly listed biotech company through growth, partnerships, and international execution. His profile combines financial rigor, board-level experience, and a strong understanding of the European biopharmaceutical ecosystem. In practical terms, Patrick Langlois represents the type of experienced non-executive director often sought by listed healthcare companies navigating strategic development and long-term value creation.